Evidence map›Paper›PMID 37771740›Full record

ArticleAntimicrobial stewardship & healthcare epidemiology : ASHE2023

Analysis of a beta-lactam allergy assessment protocol challenging diverse reported allergies managed by an antimicrobial stewardship program.

Max W Jacobs, Derek N Bremmer, Nathan R Shively, Matthew A Moffa, Tamara L Trienski, Dustin R Carr, Carley A Buchanan, Thomas L Walsh

Abstract read
In one paragraph

Article in Antimicrobial stewardship & healthcare epidemiology : ASHE, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Max W JacobsMedicine Institute, Allegheny Health Network, Pittsburgh, PA, USA.ORCID https://orcid.org/0000-0002-4447-1491
Derek N BremmerDepartment of Pharmacy, Allegheny Health Network, Pittsburgh, PA, USA.ORCID https://orcid.org/0000-0002-3989-5345
Nathan R ShivelyDivision of Infectious Diseases, Allegheny Health Network, Pittsburgh, PA, USA.ORCID https://orcid.org/0000-0001-6163-438X
Matthew A MoffaDivision of Infectious Diseases, Allegheny Health Network, Pittsburgh, PA, USA.ORCID https://orcid.org/0000-0002-6253-7490
Tamara L TrienskiDepartment of Pharmacy, Allegheny Health Network, Pittsburgh, PA, USA.ORCID https://orcid.org/0000-0002-5674-6480
Dustin R CarrDepartment of Pharmacy, Allegheny Health Network, Pittsburgh, PA, USA.ORCID https://orcid.org/0000-0001-8543-4972
Carley A BuchananDepartment of Pharmacy, Allegheny Health Network, Pittsburgh, PA, USA.
Thomas L WalshDivision of Infectious Diseases, Allegheny Health Network, Pittsburgh, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To assess the safety and efficacy of a novel beta-lactam allergy assessment algorithm managed by an antimicrobial stewardship program (ASP) team. Design: Retrospective analysis. Setting: One quaternary referral teaching hospital and one tertiary care teaching hospital in a large western Pennsylvania health network. Patients or participants: Patients who received a beta-lactam challenge dose under the beta-lactam allergy assessment algorithm. Interventions: A beta-lactam allergy assessment protocol was designed and implemented by an ASP team. The protocol risk stratified patients' reported allergies to identify patients appropriate for a challenge with a beta-lactam antibiotic. This retrospective analysis assessed the safety and efficacy of this protocol among patients receiving a challenge dose from November 2017 to July 2021. Results: Over a 45-month period, 119 total patients with either penicillin or cephalosporin allergies entered the protocol. Following a challenge dose, 106 (89.1%) patients were treated with a beta-lactam. Eleven patients had adverse reactions to a challenge dose, one of which required escalation of care to the intensive care unit. Of the patients with an unknown or low-risk reported allergy, 7/66 (10.6%) had an observed adverse reaction compared to 3/42 (7.1%) who had an observed reaction with a reported high-risk or anaphylactic allergy. Conclusions: Our implemented protocol was safe and effective, with over 90% of patients tolerating the challenge without incident and many going on to receive indicated beta-lactam therapy. This protocol may serve as a framework for other inpatient ASP teams to implement a low-barrier allergy assessment led by ASP teams.

Indexed as

allergyallergy delabelingantibioticantimicrobial stewardship programbeta-lactampenicillin

Identifiers

PMID37771740
PMCPMC10523545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.